Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RHOA | P61586 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9110969 | 0.97 | CYP3A4 (0.43) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| Ethylene Glycol SCHEMBL1923456 | 0.93 | CYP3A4 (0.41) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| Vinyl Ether SCHEMBL9746679 | 0.91 | CYP3A4 (0.39) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| SCHEMBL7094613 | 0.89 | MAPT (0.44) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| SCHEMBL7096132 | 0.89 | SOAT1 (0.65) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| 1,3-Propanediol SCHEMBL28898064 | 0.89 | TSHR (0.40) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| 1,4-Butanediol SCHEMBL28454894 | 0.89 | TSHR (0.40) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| SCHEMBL9928 | 0.88 | CYP3A4 (0.48) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL692505 | 0.87 | CYP3A4 (0.41) | CYP3A4SOAT1TSHRMAPTCACNA1B | |
| SCHEMBL3277365 | 0.87 | MAPT (0.39) | CYP3A4SOAT1TSHRMAPTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4049841-B1 | HYBRID RESIN COMPOSITION | CUBICURE GMBH (AT) | 2026-03-18 | — | — | EP | claimed |
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12390987-B2 | Hybrid resin composition for the 3D-printing of objects | CUBICURE GMBH (AT) | 2025-08-19 | — | — | US | claimed |
| CN-119948642-A | Carbon dioxide saturated electrolyte for energy storage device and method thereof | 特斯拉公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025071268-A1 | POLYESTER RESIN HAVING EXCELLENT MECHANICAL PROPERTIES AND BIODEGRADABILITY, AND PREPARATION METHOD THEREFOR | 주식회사 삼양사 | 2025-04-03 | — | — | WO | claimed |
| CN-119419346-A | Solid electrolyte and preparation method and application thereof | 香港科技大学 | 2025-02-11 | — | — | CN | claimed |
| WO-2024182268-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | claimed |
| US-20240198582-A1 | HYBRID RESIN COMPOSITION FOR THE 3D-PRINTING OF OBJECTS | CUBICURE GMBH (AT) | 2024-06-20 | — | — | US | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| WO-2024072964-A1 | CARBON DIOXIDE SATURATED ELECTROLYTES FOR ENERGY STORAGE DEVICE, AND METHODS THEREOF | TESLA, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| EP-0767819-A4 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI POINT MEDICAL CORP (US) | 1997-09-24 | — | — | EP | claimed |
| EP-0767819-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| EP-0756590-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | Novartis AG (CH) | 1997-02-05 | — | — | EP | claimed |
| WO-1996000760-A1 | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS | TRI-POINT MEDICAL CORPORATION (US) | 1996-01-11 | — | — | WO | claimed |
| WO-1995029150-A1 | SYNTHESIS OF PROTOTYPES FOR RENIN INHIBITORS | CIBA-GEIGY AG (CH) | 1995-11-02 | — | — | WO | claimed |
| EP-0463969-B1 | New compounds of 4-aminobutyric acid, process for their preparation and pharmaceutical preparations containing them | ADIR (FR) | 1995-02-08 | — | — | EP | claimed |
| EP-0382641-B1 | Process for the preparation of ditertioalkyl dicarbonate | RHONE POULENC CHIMIE (FR) | 1994-07-06 | — | — | EP | claimed |
| EP-0372635-B1 | Method of preparing dialkyl and diallyl dicarbonates | AKZO NV (NL) | 1994-04-27 | — | — | EP | claimed |
| US-5243052-A | Mixed carbonate ester derivatives of quinophthalone dyes and their preparation | POLAROID CORPORATION (US) | 1993-09-07 | — | — | US | claimed |
| EP-0328968-A2 | Process for the preparation of 4-acylamino-2-amino alkoxy benzenes | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | CYP3A4 4467/4885SOAT1 192/4885TSHR 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.